Caspase-1:The inflammasome and beyond by Sollberger, Gabriel et al.
                                                                    
University of Dundee
Caspase-1
Sollberger, Gabriel; Strittmatter, Gerhard E.; Garstkiewicz, Martha; Sand, Jennifer; Beer,
Hans Dietmar
Published in:
Innate Immunity
DOI:
10.1177/1753425913484374
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Sollberger, G., Strittmatter, G. E., Garstkiewicz, M., Sand, J., & Beer, H. D. (2014). Caspase-1: The
inflammasome and beyond. Innate Immunity, 20(2), 115-125. https://doi.org/10.1177/1753425913484374
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Sep. 2020
Review Article
Caspase-1: The inflammasome and beyond
Gabriel Sollberger, Gerhard E Strittmatter,
Martha Garstkiewicz, Jennifer Sand and Hans-Dietmar Beer
Abstract
Caspase-1 plays a fundamental role in innate immunity and in several important inflammatory diseases as the protease
activates the pro-inflammatory cytokines proIL-1b and proIL-18. Caspase-1 itself is activated in different inflammasome
complexes, which assemble in response to a variety of exogenous and endogenous stressors. More recently, pyroptosis,
a caspase-1-dependent type of programmed cell death, has been identified that is able to support secreted IL-1 and IL-18
in triggering an inflammatory response. Whereas these ‘canonical’ activities are well appreciated, this review also high-
lights less-known pathways and molecules activated by caspase-1. There is evidence that caspase-1 supports cell survival
by activation of NF-kB, induction of membrane repair and regulation of unconventional secretion of certain proteins. The
physiologic effects of processing of other downstream targets, such as proteins involved in glycolysis or activation of
caspase-7, are less well understood. However, there is increasing evidence that caspase-1 contributes to innate and
adaptive immunologic defense mechanisms, repair and pathologic conditions by the regulation of several different and
partially opposing pathways.
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Introduction
Caspases
Caspases (cysteinyl aspartic proteases) comprise a
family of cysteine proteases (caspase-1 to caspase-10,
caspase-12 and caspase-14 in humans), which are
known mainly for their essential roles in apoptosis.1,2
This form of programmed cell death is characterized by
regulated caspase-dependent self-digestion of a cell
resulting in membrane-surrounded apoptotic bodies.
The dying cells expose ‘find-me’ and ‘eat-me’ signals,
thereby mediating their engulfment by phagocytes,
which is considered to be immunologically silent.3
Caspases are expressed as inactive precursors with
an amino terminal prosequence.4 The prosequence
may consist of homotypic protein–protein interaction
domains, such as the death effector domain (DED) or
the caspase activation and recruitment domain
(CARD).1 DED and CARD comprise families of the
death domain (DD) fold, characterized by six anti-par-
allel a-helices, which form a Greek key. Family mem-
bers can, but do not necessarily have to, allow
interactions with members of the same family.
However, they never bind to a member of a different
family. Interestingly, the DD fold is only found in
proteins involved in apoptosis and inflammation,
which suggests a special, and most likely evolutionarily
conserved, connection between both pathways.1
Apoptotic caspases with long prodomains (caspase-2,
and caspases 8–10) are called upstream or initiator cas-
pases as they are able to react to death signals by DD
fold-mediated assembly into macromolecular com-
plexes and subsequent self-activation. Once activated,
initiators process and thereby activate the downstream
or effector caspases (caspase-3, and caspases 6 and 7),
which contain only short prosequences lacking a DD
fold. In turn, activated effector caspases execute cell
death through cleavage of numerous substrates. In con-
trast to effector caspases, which require proteolytic pro-
cessing to be activated, upstream caspases, such as
caspase-9, can also be active without proteolytic
cleavage.1,2
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Whereas apoptotic caspases are expressed ubiqui-
tously, expression of caspase-14 is restricted to strati-
fied epithelia, such as the skin.5,6 Caspase-14 exerts a
very specialized function, namely the cleavage of pro-
fillagrin, which is needed for the proper formation of
the cornified envelope, and thereby protects the cells of
the skin from UVB irradiation and water loss.5,6
All other caspases (caspase-1, caspases 4 and 5, and
caspase-12 in humans) are called inflammatory cas-
pases. They are transcribed from the same chromo-
somal locus, contain an amino terminal CARD, and
are involved in inflammation through the regulation
of activation of the pro-inflammatory cytokines
proIL-1b and proIL-18.7,8 Caspase-12 lacks catalytic
activity, inhibits caspase-1 and its ablation in mice con-
fers resistance against sepsis,9,10 although there is also
evidence for an involvement in endoplasmic reticulum
(ER) stress-induced apoptosis.11
Caspase-1
Caspase-1 was identified in 1989 as the protease able to
cleave the pro-inflammatory cytokine proIL-1b.12,13
Three years later its cDNA was cloned as IL-1b-con-
verting enzyme (ICE).14 It turned out that ICE has
28% similarity to the Caenorhabditis elegans protein
CED-3, which is essential for apoptosis. Although
overexpressed ICE is able to induce apoptosis,15 mice
lacking caspase-1 do not show a spontaneous pheno-
type, demonstrating that expression of caspase-1 is
dispensable for apoptosis during embryonic develop-
ment.16,17 Today, it is generally accepted that endogen-
ous caspase-1 is not involved in apoptosis.3,18,19
Nevertheless, some publications claimed a requirement
of caspase-1 for apoptosis in neuronal or endothelial
cells.20–22 This discrepancy may be, at least partially,
explained by the use of different methods for the detec-
tion of cell death as caspase-1 activation can induce a
lytic form of programmed cell death termed pyroptosis,
which can be distinguished clearly from apoptosis (see
later).
Besides proIL-1b, caspase-1 can also activate proIL-
18, another member of the IL-1 family.23,24 However,
there are several reports demonstrating that, in mice,
proIL-1b25,26 and proIL-1827–29 can be activated in the
absence of caspase-1 by other proteases, particularly in
neutrophils.
Interestingly, proIL-1b and proIL-18 are the only
substrates of caspase-1 confirmed in vitro and in vivo
under physiologic or pathologic conditions. This stands
in contrast to more than 600 verified substrates of
apoptotic executioner caspases.30 Although several
proteomics approaches led to the identification of
novel caspase-1 cleavage products,31–33 the relevance
of these cleavage events under physiologic conditions
remains to be determined. One reason for the identifi-
cation of novel substrates in these studies might be the
very high, and most likely non-physiologic, concentra-
tions of caspase-1 that have been used. It has been
demonstrated recently that caspase-1 has a low
substrate specificity at high concentrations, which is
drastically increased by lowering its concentration.30
Most importantly, the half-life of active caspase-1 is
very low (about 50 times lower than the half-life of
active caspase-3), suggesting that high concentrations,
and therefore low specificity, will not be reached under
physiologic conditions.30 Recently, it has further been
suggested that substrate binding triggers dimerization
and activation of mature caspase-1, but not of caspase-
3. This may reflect the fact that caspase-1 cleaves a
much smaller number of proteins than caspase-3.34
IL-1
Inflammation is an essential protective attempt of an
organism to restore a homeostatic state after its
disturbance by a harmful stimulus. Tissue damage,
infection and other immunologic challenges rapidly
induce an inflammatory response, which represents
the activation of the innate immune system. The pro-
inflammatory cytokine IL-1 (IL-1a and IL-1b) plays an
important role in these fundamental and beneficial pro-
cesses.35 IL-1 induces the expression of adhesion mol-
ecules on mesenchymal and endothelial cells, which
triggers infiltration of inflammatory and immune
cells.35 In addition, IL-1 causes fever, vasodilation,
hypotension and enhances pain sensitivity. Expression
and activity of IL-1 are tightly controlled at the tran-
scriptional, as well as at the post-transcriptional,
level.36 Biological responses of IL-1 are mediated by
signaling via IL-1 receptor type I (IL-1RI).36 IL-1a
and IL-1b are both expressed initially as pro-peptides
with an amino terminal extension. ProIL-1b is not able
to bind and activate IL-1RI, whereas proIL-1a pos-
sesses biological activity, which is further enhanced by
limited proteolysis.35.37 Caspase-1 is described as the
principal activator of proIL-1b16,17,35 and, therefore,
a central regulator of the inflammatory response. In
addition, caspase-1 can activate proIL-18.
Interestingly, proIL-1a, proIL-1b and proIL-18 lack a
signal peptide for protein secretion and are released
from the cell by a poorly understood pathway termed
unconventional protein secretion, which occurs inde-
pendently of the classical ER/Golgi pathway.36,38 IL-1
activity is counteracted by expression of IL-1R antag-
onist (IL-1Ra), which possesses a signal peptide and
is secreted constitutively via the classical pathway.35
IL-1Ra binds to IL-1RI, thereby preventing binding
of IL-1a and IL-1b, and suppressing an inflammatory
response in vivo, as IL-1Ra cannot induce signal trans-
duction.35 Mice lacking IL-1a and IL-1b do not
develop a spontaneous phenotype. However, mice lack-
ing expression of IL-1Ra suffer from arthritis, arteritis
and skin inflammation. In humans, deficiency in
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IL-1Ra (DIRA) causes a life-threatening auto-inflam-
mation, affecting mainly the skin and the bones.39,40
This demonstrates that IL-1Ra is required to control
the activity of IL-1 also in the human organism. DIRA
is treated successfully with a recombinant form of
IL-1Ra (Anakinra, Kineret), which was approved ini-
tially for the treatment of arthritis.35,41 Anakinra and
other IL-1 blockers are effective in a range of important
modern diseases, such as type 2 diabetes mellitus or
gout, as well as other sterile inflammations now collect-
ively called autoinflammatory diseases, which are all
IL-1-mediated.35,41
The NLRP1 inflammasome
In 2002, a protein complex required for the activation
of caspase-1 and subsequent processing of proIL-1b
was identified and termed inflammasome.42 This new
complex consisted of caspases 1 and 5, the adapter pro-
tein apoptosis associated speck-like protein containing
a CARD (Asc) and NACHT, leucine-rich repeats
(LRR) and pyrin domains-containing protein 1
(NLRP1) or NALP1, the latter most likely acting as
backbone protein and as sensor for the assembly.43
Although, at that time, no ligand for NLRP1 was
known, these results suggested that NLRP1 acts like a
cytoplasmic Toll-like receptor (TLR) that induces
inflammation through activation of caspase-1, proIL-
1b and proIL-18 instead of NF-kB. TLRs are trans-
membrane receptors located at the cell surface or on
endosomes, whose LRRs bind to conserved molecules
from pathogens [pathogen-associated molecular pat-
terns (PAMPs)], but also to endogenous molecules
released by damaged cells [danger or damage-asso-
ciated molecular patterns (DAMPs)]. This binding
induces signal transduction, followed by activation of
NF-kB and transcription of pro-inflammatory target
genes.44 NLRP1 belongs to the family of Nod-like
receptors (NLRs), which constitutes 22 members in
humans and 34 in mice.43 It binds the CARD of pro-
caspase-5 with its carboxyterminal CARD and the
pyrin domain (PYD) of Asc with its amino terminal
PYD. In turn, Asc links procaspase-1 to the complex
via CARD–CARD interactions.42,43 Therefore, both
caspases come into close proximity and are able to acti-
vate each other. In vitro, muramyl dipeptide (MDP), a
peptidoglycan constituent of bacteria, and ribonucleo-
side triphosphates induce oligomerization of NLRP1
and caspase-1 followed by activation of the latter,
which is enhanced by Asc.45 Lethal toxin secreted by
Bacillus anthracis activates the NLRP1 inflammasome
in murine macrophages.46 Signaling downstream of IL-
1RI and pyroptosis (see later) have been suggested to
contribute to caspase-1-dependent resistance against B.
anthracis.47,48 However, the molecular mechanisms
leading to NLRP1 inflammasome activation are not
known as there is no evidence that either MDP or
lethal factor from B. anthracis bind directly to
NLRP1.45 In human keratinocytes, NLRP1 expression
is required for UVB-induced secretion of IL-1b.49 An
important role of NLRP1 in the skin is further sug-
gested by the observation that single-nucleotide poly-
morphisms in the nlrp1 gene are associated with vitiligo,
an autoimmune disorder involving destruction of mel-
anin-producing melanocytes in the skin.50
The NLRP3 inflammasome
The NLRP3 (also known as NALP3 or cryopyrin)
inflammasome is the most important type of inflamma-
some complex as it is activated by many different
PAMPs and DAMPs.19 Several bacterial pathogens,
such as Escherichia coli, Vibrio cholera and
Staphylococcus aureus; fungal pathogens, such as
Candida albicans and Aspergillus fumigatus; viruses,
like influenza A and vesicular stomatitis virus; and
parasites, such as Schistosoma mansoni, activate cas-
pase-1 dependent on NLRP3 and Asc expression,
which, in turn, induces secretion of active IL-1b and
IL-18.51,52 Recently, it has been reported that expres-
sion and activity of caspase-4 are required for NLRP3
inflammasome activation in THP-1 cells and human
keratinocytes.53 NLRP3 can sense prokaryotic
mRNA, present only in living bacteria, now defined
as a special class of viability-associated PAMPs.54 It
has also been suggested that ER stress activates the
NLRP3 inflammasome.55 Most importantly, the
NLRP3 complex is also activated by different types of
crystals and particles in phagocytic cells.19,51 Examples
are monosodium urate crystals, which are the causing
agent of gouty inflammations, and islet amyloid poly-
peptides, which activate the NLRP3 inflammasome in
patients with type 2 diabetes mellitus. IL-1 blockers are
effective in the treatment of these patients, thus demon-
strating a fundamental role of inflammasome-generated
IL-1 activity in modern human diseases.19,35
Furthermore, amyloid b aggregates activate the
NLRP3 inflammasome in microglia, asbestos and
silica particles in alveolar macrophages, or cholesterol
crystals in macrophages, which plays an important role
in Alzheimer’s disease, pulmonary fibrotic disorders
and atherosclerosis, respectively.19 An involvement of
NLRP3 in inflammatory diseases is further demon-
strated by the fact that mutations of the nlrp3 gene
are the cause of different auto-inflammatory periodic
syndromes, which are now collectively called cryo-
pyrin-associated periodic syndromes (CAPS). CAPS
patients suffer from rashes, fever and fatigue; in
severe cases there can be hearing loss, mental impair-
ment or bone deformities. These patients are free of
symptoms as long as Anakinra or other IL-1 blockers
are administered.35,56
A heavily discussed question is how all these differ-
ent PAMPs and DAMPs induce NLRP3
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inflammasome activation at the molecular level. It is
clear that, in contrast to keratinocytes, expression of
proIL-1b and NLRP3 has to be induced in macro-
phages and dendritic cells prior to inflammasome acti-
vation. Therefore, these cells require an activation of
NF-kB triggered by stimulation with TNF-a, IFN-g or
TLR agonists.49,57,58 As NLRP3 ligands are highly
diverse in their chemical nature and size, a direct bind-
ing of DAMPs and PAMPs to NLRP3 is extremely
unlikely and could not be demonstrated so far.19
Therefore, more indirect pathways have been sug-
gested, which integrate the different triggers of inflam-
masome assembly into ion fluxes, phagosomal
destabilization and the generation of reactive oxygen
species (ROS).19,51 For example, NLRP3-activating
crystals are phagocytosed, which results – due to inef-
ficient clearance – in phagosomal and lysosomal
damage, and in cathepsin B-mediated NLRP3 inflam-
masome assembly.58 However, particle-induced IL-1b
secretion from murine cathepsin B-deficient cells is
normal.59 All NLRP3 activators induce the generation
of ROS. Therefore, it has been suggested that ROS-
induced binding of thioredoxin-interacting protein
(TXNIP) to NLRP3 triggers inflammasome activa-
tion.60 The source of ROS is most likely
mitochondria.61–63 However, it is not known whether
ROS are always necessary, and particularly if the gen-
eration of ROS is always sufficient for the activation of
the NLRP3 inflammasome. Other proteins involved in
the regulation of NLRP3 inflammasome activation are
the protein kinase R (PKR) and guanylate binding pro-
tein 5 (GBP5). GBP5 is required for NLRP3 inflamma-
some responses to pathogenic bacteria and soluble (but
not to crystalline) activators.64 In contrast, ablation of
PKR expression prevents not only activation of the
NLRP3 inflammasome, but also of the NLRP1,
NLRC4 and absent in melanoma 2 (AIM2) inflamma-
somes (Figure 1).65 However, a recent report claims
that PKR is dispensable for inflammasome activation
in macrophages.66
The NLRC4 inflammasome
NLRC4 (NLR family CARD domain-containing pro-
tein 4, also known as ICE-protease activating factor) is
an NLR required exclusively for bacterial-induced cas-
pase-1 activation and subsequent inflammation.19,67
Asc expression is needed for caspase-1-mediated and
NLRC4-dependent activation of proIL-1b and proIL-
18, but most likely not for caspase-1-dependent cell
anthrax lethal toxin
MDP
flagellin
components of T3SS
ATP
PAMPs
DAMPs
crystalline
particles
P2X7
K+
procaspase-1
procaspase-5
procaspase-1
procaspase-1
cytoplasmic dsDNA
cell membrane
AIM2
IFI16
IFI16
lysosomal damage
intestinal microbes?
procaspase-4
caspase-1
FIINDBIRHIN200LRRNBDPYDcaspase-1 p10/p20CARD
proIL-1b
proIL-18
IL-1b
IL-18
procaspase-1
procaspase-1
viral dsDNA
nucleus
procaspase-4
NLRP1
NLRC4
NLRP3
NLRP6
NAIP5
NAIP6
NAIP2
Asc
Asc
ROS
PAMPs
DAMPs
Asc
Asc
Asc
Asc
procaspase-1
procaspase-1
Figure 1. The different types of inflammasomes. The NLRs NLRP1, NLRC4, NLRP3 and NLRP6, and the HIN200 proteins AIM2 and
IFI16 build up inflammasomes upon sensing different PAMPs or DAMPs. Whereas AIM2 and IFI16 assemble through binding of
pathogen-derived dsDNA, more indirect mechanisms induce formation of the other types of inflammasomes. NLRC4 is activated by
binding to NAIPs, NAIP5 and NAIP6 sense flagellin, and NAIP2 the T3SS rod protein. The NLRP3 inflammasome is activated by many
different DAMPs and PAMPs. Here, generation of ROS, efflux of K+ or cathepsin B release upon lysosomal damage may trigger
complex formation. The stimulus that results in assembly of the NLRP6 inflammasome remains to be identified. All inflammasomes
recruit Asc and caspase-1, what induces activation of the protease, subsequent activation of proIL-1b and proIL-18, and, finally,
secretion of the active cytokines.
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death (see later). 52 The NLRC4 inflammasome is acti-
vated by flagellin, the principal substituent of the bac-
terial flagellum, during infection of macrophages with
Salmonella Typhimurium, Listeria monocytogenes and
Legionella pneumophila, but also by the type III secre-
tion system (T3SS) rod protein from a range of bac-
teria.67,68 Interestingly, these bacterial products are
sensed in murine macrophages by NLR family, apop-
tosis inhibitory proteins (NAIPs), also known as bacu-
loviral IAP repeat (BIR)-containing 1, which are then
recruited to NLRC4, thereby defining the specificity of
the NLRC4 inflammasome.19 NAIP5 and NAIP6 are
required for sensing of flagellin, NAIP2 for the T3SS
rod protein.69,70 In contrast, there is only one human
NAIP, which neither binds to flagellin nor to T3SS rod
proteins, but to the T3SS needle subunit from several
bacteria.70 Recently, it has been shown that NLRC4 is
phosphorylated – what is required for its ability to acti-
vate caspase-1 – thus representing a further level of
complexity in NLRC4 inflammasome activation.71
The AIM2 inflammasome
AIM2 (absent in melanoma 2) is a cytoplasmic member
of the hematopoietic expression, interferon-inducible,
nuclear localization and a 200 amino acid repeat
(HIN200) family that consists of an amino terminal
PYD and a carboxyterminal HIN200 motif. The
latter can bind to double-stranded (ds) DNA.72 AIM2
expression is induced by type I and II IFNs, which play
an important role in defense against viral infections.
AIM2 can bind to transfected or pathogen-derived
cytoplasmic dsDNA and subsequently recruits Asc by
PYD–PYD interaction, which, in turn, binds caspase-1.
This results, most likely, in oligomerization of the com-
plex, in activation of caspase-1 and in secretion of
active IL-1b and IL-18. The AIM2 inflammasome is
activated by Francisella tularensis, DNA viruses, such
as cytomegalovirus and vaccinia virus, as well as by L.
monocytogenes, although the latter requires expression
of NLRP3 and NLRC4 for maximal activation of cas-
pase-1.73–75 In contrast to AIM2, the HIN200 family
member IFN-inducible (IFI) 16 is located mainly in the
nucleus, where it is able to detect viral dsDNA and
trigger a type I IFN response.76 During primary and
latent infection IFI16 binds to Kaposi’s sarcoma-asso-
ciated herpes virus DNA. Then, it translocates to the
cytoplasm, where it assembles an inflammasome com-
plex with Asc and caspase-1.77,78 An interesting ques-
tion is how IFI16 can discriminate between self and
pathogen-derived DNA.73
The NLRP6 inflammasome
Recently, it was shown that mice deficient in NLRP6
are more susceptible to dextran sodium sulfate (DSS)-
induced colitis, a model for an inflammatory intestinal
disease, and subsequent tumorigenesis.79 The reason
for this unexpected phenotype is most likely an aber-
rant microflora of the gastrointestinal tract.79,80 In add-
ition, not only NLRP6 but also Asc, caspase-1 and
proIL-18 expression are required for a ‘healthy’ micro-
flora, suggesting that NLRP6 forms an inflammasome,
which protects against colitis and colitis-associated
tumorigenesis through IL-18. Interestingly, the pheno-
type was transferable to wild type mice, which were
co-housed with NLRP6-, caspase-1- or Asc-deficient
animals.79 It has been demonstrated that IL-18, rather
than IL-1, is the more important cytokine in
DSS-induced colitis,81,82 although other publications
based on a different mouse strain reported less suscep-
tibility in caspase-1-deficient mice.83 Apart from using
different strains, these conflicting results may also be
explained by different gastrointestinal microfloras in
different animal facilities. Surprisingly, mice lacking
NLRP6 expression are more resistant to infection
with certain bacterial pathogens, most likely as
NLRP6 expression reduces the levels of NF-kB- and
mitogen-activated protein kinase (MAPK)-dependent
cytokines and chemokines.84
Pyroptosis
Overexpression of caspase-1 has been suggested to
induce apoptosis.15 Caspase-1 has also been implicated
in neuronal and endothelial programmed cell
death.20,21,22 More than 20 years ago, it was shown
that macrophages infected with Shigella flexneri or S.
Typhimurium undergo apoptosis.85 The classification
of apoptotic cell death was based on morphologic fea-
tures, DNA fragmentation, chromatin condensation
and on the requirement for caspase-1.3 After generation
of caspase-1-deficient mice it turned out that caspase-1
expression is dispensable for cell death induced by
known apoptotic agents and for apoptosis during
embryonic development.16,17 A more careful character-
ization of pathogen-induced cell death of macrophages
revealed clear differences to apoptosis.3,18 This type of
cell death, now termed pyroptosis, is considered to be
dependent only on caspase-1, but not on apoptotic cas-
pases. In addition, caspase-1 does not cleave, and
thereby activate, caspase-3 during pyroptosis. Most
importantly, in contrast to apoptosis, pyroptotic cell
death is characterized by an increase in cell size due
to osmotic swelling and the subsequent rupture of the
cytoplasmic membrane, whereas the mitochondrial
membrane remains intact. This results in the release
of pro-inflammatory molecules, such as ATP, or pro-
teins, such as proIL-1a and HMGB1, which are able to
recruit neutrophils and induce inflammation. In con-
trast, apoptosis is considered immunologically silent
as apoptotic cells attract macrophages to find and
phagocytose them without mounting an inflammatory
response. Experimentally, apoptotic cell death can be
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discriminated from pyroptosis by detection of caspase-3
processing, whereas both types of cell death are char-
acterized by DNA fragmentation.3 Interestingly, cas-
pase-1 does not require processing in order to become
active for execution of pyroptosis, in contrast to activ-
ity towards proIL-1b and proIL-18, where processing
of the protease has to take place.86 In addition, pyrop-
tosis, if triggered by NLRC4, does not require expres-
sion of Asc,86 whereas Asc is needed for NLRP3 and
AIM2 inflammasome-driven pyroptosis.3,86 Reports
about pyroptosis in vivo are rare, but an elegant study
in mice demonstrated that S. Typhimurium induced
NLRC4-dependent pyroptosis in macrophages leads
to the subsequent uptake of the released bacteria by
neutrophils, which is required for clearance of the infec-
tion.87 Murine neutrophils do not undergo S.
Typhimurium-induced pyroptosis as they do not
express NLRC4.87 It is still unclear whether pyroptosis
only occurs in macrophages and dendritic cells, or also
in other cell types, and whether all inflammasomes can
trigger pyroptosis.3,18,51 Interestingly, it has been
claimed that pyroptosis depends only on the catalytic
activity of caspase-1, but not on caspase-11.87
However, recently, it turned out that the caspase-1-defi-
cient mice used so far also lack expression of caspase-11
and that caspase-11, rather than caspase-1, confers
susceptibility to sepsis and cell death.73,88
Glycolysis and caspase-7
In order to determine the molecular mechanisms of
pyroptosis downstream of activation of caspase-1,
screens led to the identification of novel caspase-1
substrates.31–33 In contrast to caspase-3, recombinant
caspase-1 cleaves several enzymes required for glycoly-
sis, such as aldolase, GAPDH, triose-phosphate isom-
erase and a-enolase.33 Glycolysis is essential for the
synthesis of ATP, which is required for macrophage
survival and activation. Although in vitro the caspase-
1 concentration needed for cleavage of GAPDH
is higher by a factor of 50 than for cleavage of proIL-
1b, this cleavage seems to occur at a consensus site and
to inactivate GAPDH. Most importantly, processing of
GAPDH is also detected in Salmonella-infected
macrophages and in the diaphragm muscle of mice
undergoing septic shock, suggesting a novel function
of caspase-1 during pyroptosis and septic shock.33
However, whether inactivation of glycolysis contributes
to the protection against pathogens or plays an impor-
tant role in sepsis is not known.
Caspase-7 is an effector in apoptosis with a similar
function as caspase-3. Recently, it has been shown that
caspase-7, but not caspase-3, is activated by caspase-1
in vitro and in vivo.31 This cleavage requires expression
of NLRP3, NLRC4, Asc and caspase-1, when macro-
phages are stimulated with NLRP3 or NLRC4 activa-
tors, respectively.31 Interestingly, restriction of
L. pneumophila replication is reduced in caspase-
7-deficient macrophages in comparison to wild type
cells. Certainly, this is most likely due to a function
of caspase-7 in the fusion of bacteria-containing phago-
somes with lysosomes, rather than in pyroptosis.31,89
Murine caspase-11 also promotes this fusion event
through the modulation of actin polymerization.90 As
S. Typhimurium-induced pyroptosis proceeds normally
in cells lacking expression of both caspases 3 and 7, a
possible function of caspase-7 in pyroptosis remains
to be demonstrated.91 The induction of expression
of NF-kB target genes by inflammasome-induced
caspase-7 activation points into a different direction.92
Interestingly, caspase-1 mediated activation of caspase-
7 results in translocation of the latter to the nucleus,
where it cleaves PARP1. This induces PARP1 release
from chromatin, chromatin decondensation and, even-
tually, expression of NF-kB target genes.92
Caspase-1 activates lipid metabolic pathways
Although caspase-1 supports cell death of immune cells
infected by certain pathogens (see earlier), it can also
support survival and confer resistance to pathogenic
bacteria.93,94 Some bacteria express pore-forming
toxins as virulence factors, which create holes of vari-
ous sizes in the plasma membrane of the host cell.
Aerolysin secreted by Aeromonas species heptamerizes
into a ring, which results in the exposure of hydropho-
bic surfaces allowing the insertion into the plasma
membrane.93 These pores lead to the efflux of intracel-
lular potassium, which triggers the NLRP3-, NLRC4-
and Asc-dependent activation of caspase-1.
Interestingly, active caspase-1 is required for activation
of sterol regulatory element binding proteins
(SREBPs), transcription factors that function predom-
inantly in cholesterol and fatty acid biogenesis. Inactive
SREBPs are located in the ER membrane. Upon chol-
esterol depletion, which induces their activation,
SREBPs move to the Golgi apparatus, where they are
processed and liberated by two Golgi proteases.
Eventually, SREBPs translocate to the nucleus, where
they induce the expression of target genes and switch on
lipid metabolic pathways (Figure 2).93,94 Aerolysin-
induced SREBP activation is blocked by inhibition of
caspase-1 activity and by knockdown of expression of
caspase-1, NLRP3, NLRC4 and Asc. Most import-
antly, this increases aerolysin-induced cell death,
which most likely does not represent apoptosis, demon-
strating an unexpected role of caspase-1 in survival.
Most likely, this is due to repair of the damaged
plasma membrane through the SREBP-dependent syn-
thesis of lipids. However, the molecular mechanism of
how caspase-1 activates SREBPs, which most likely
occurs indirectly, is completely unknown. The fact that
caspase-1 activity is needed suggests the existence of an
unknown substrate of the protease, which, in turn,
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activates SREBPs. In addition, the role of caspase-1 in
survival has been demonstrated only in Chinese hamster
ovary and HeLa cells,93 whereas pyroptosis occurs in
macrophages and dendritic cells (see earlier). It would
be interesting to know whether caspase-1 is also able to
increase survival in macrophages, which are the primary
cells involved in defense against pathogens.94
Unconventional protein secretion
Proteins, such as IL-1a, IL-1b, IL-18, or fibroblast
growth factor (FGF)-2 clearly fulfill extracellular func-
tions, but lack a signal peptide, which would allow their
ER/Golgi-dependent secretion from the cell.38
Nevertheless, these proteins get secreted through the
plasma membrane. However, they use a special and
only poorly understood pathway termed unconven-
tional protein secretion. The difficulty of the analysis
of this pathway is to discriminate between regulated
(unconventional) secretion and passive release owing
to cell lysis. This is particularly true because unconven-
tional secretion can be induced by stressors, which have
also cytotoxic effects resulting in cell death and lysis.
Interestingly, macrophages deficient for caspase-1 are
not only defective in IL-1b and IL-18 secretion, but,
surprisingly, also in the release of proIL-1a.16,17,95
ProIL-1a secretion requires expression of caspase-1,
but also caspase-1 activity, suggesting the existence of
an unknown substrate involved in the regulation of
unconventional secretion of at least proIL-1a.96
Consequently, secretion of proIL-1a also requires
expression of other inflammasome proteins, which are
needed for activation of caspase-1. UVB irradiation
activates the NLRP3 and NLRP1 inflammasome in
human primary keratinocytes, which triggers secretion
of IL-1 and IL-18 and unconventional secretion of
inflammasome proteins – all lacking a signal peptide.49
The advantage of UVB-irradiated keratinocytes over
activated macrophages and dendritic cells is the robust-
ness of the former, which allows distinguishing between
unconventional secretion and passive release.49
Interestingly, secretome analysis of UVB-irradiated
keratinocytes revealed caspase-1-dependent secretion
of several proteins, whose unconventional secretion
has already been described, as well as secretion of sev-
eral other leaderless proteins.96 These proteins are
involved in repair processes, ROS detoxification and
apoptosis. Therefore, caspase-1 activity directly links
IL-1- and IL-18-dependent inflammation with these
processes. It is tempting to speculate that the secretion
of pro-apoptotic proteins, such as Bid, enhances the
survival of the secreting cells, which has also been sug-
gested for secretion of caspase-1 itself (unpublished
results).7,43,96 Unconventional protein secretion is an
at least partially evolutionarily conserved process,
which is mediated in Dictyostelium by autophago-
somes.97 Recently, it has been demonstrated that
unconventional secretion of IL-1b and other proteins
by mammalian cells is supported by autophagy.98
However, these findings are in contrast to reports that
suggest that autophagy suppresses inflammasome acti-
vation and, therefore, secretion of IL-1b.62,63
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procaspase-1 procaspase-7
IL-1 TLR2/4 ligands
unconventional protein secretion
cell membrane
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cleaved MAL1kB
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nucleus nucleus nucleus
transcription of NF-kB target genes membrane repair survival
MAL
active
caspase-1
active
caspase-1
caspase-7
active
caspase-1
cleaved
PARP
PARP
GAPDH
Figure 2. Pathways targeted by caspase-1. Upon activation, caspase-1 cleaves proIL-1b and proIL-18, and the active cytokines induce
inflammation after secretion. Activity of the protease is also needed for unconventional secretion of many other leaderless proteins
supporting inflammation, repair and, most likely, survival. In addition, pore-forming toxins induce the activation of SREBPs by active
caspase-1, which are required for the repair of the plasma membrane and subsequent survival. Pyroptosis represents a caspase-1
effector mechanism causing a lytic form of cell death with release of pro-inflammatory molecules. Caspase-7 is a substrate of caspase-1
that cleaves PARP, resulting in transcription of NF-kB target genes, which may foster inflammation and survival. Caspase-1 triggers NF-
kB activation by two additional mechanisms, requiring either cleavage of MAL by active caspase-1 or RIP2 activation by CARD–CARD
interaction.
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Caspase-1 and NF-B
Caspase-1 has been implicated in the regulation of NF-
kB. Transcription factors of this class are involved in
inflammation, regulation of immune responses, differ-
entiation and apoptosis.99 In unstimulated cells, NF-kB
is retained in the cytoplasm through binding to the IkB
inhibitor. Upon activation, IkB gets phosphorylated by
the IkB kinase (IKK) complex, which results in poly-
ubiquitination and proteasomal degradation of IkB.
The liberated NF-kB translocates to the nucleus and
induces expression of target genes, which are inflamma-
tion-related or anti-apoptotic. Pathogen-derived prod-
ucts, which are agonists of TLRs, as well as TNF-a and
IL-1, which stimulate their respective receptors, lead to
activation of NF-kB through distinct signaling path-
ways.100 Therefore, a pathway, by which caspase-1
mediates NF-kB activation, is triggered by inflamma-
some-activated, caspase-1-dependent IL-1 secretion.35
However, macrophages isolated from mice lacking
expression of caspase-1 have impaired NF-kB activa-
tion when stimulated with the TLR4 agonist LPS,
which does not result in activation of caspase-1.101,102
NF-kB activation is rescued by overexpression of an
enzymatically inactive variant of caspase-1, which dem-
onstrates that caspase-1 enhances NF-kB activation
independently of the active site cysteine.101 In addition,
overexpression of inactive caspase-1 enhances NF-kB
activity in 293 cells.100 This effect is CARD-dependent
through interaction with the CARD-containing kinase
RIP2, resulting in NF-kB activation via IKK recruit-
ment.100 The inhibitor of caspase-1 CARD only protein
(COP) also interacts with RIP2 and thereby mediates
NF-kB activation. In contrast, the CARD-containing
proteins ICEBERG, and caspases 11 and 12 do not
activate the transcription factor, suggesting that cas-
pase-1-dependent activation of NF-kB is a specific
event.100 Asc, which is required for activation of cas-
pase-1 in inflammasome complexes, has an inhibitory
effect on NF-kB.101,102 Although the interaction of the
CARD of caspase-1 with Asc and RIP2 is mediated by
different amino acids,103 caspase-1 interacts either with
Asc or with RIP2, suggesting that Asc may direct cas-
pase-1 away from RIP2, thereby inhibiting direct NF-
kB activation, while inflammasome-mediated IL-1 pro-
duction is induced.101 This pathway might explain the
recent report of patients carrying mutations of caspase-
1.104 Although all these mutations drastically decrease
the enzymatic activity of caspase-1, reflected by reduced
processing of the enzyme itself and by diminished secre-
tion of mature IL-1b, the symptoms of the carriers are
similar to those suffering from IL-1-mediated auto-
inflammatory diseases.104 It is tempting to speculate
that a possibly more pronounced activation of NF-kB
by these caspase-1 variants underlies the inflammatory
phenotype, although additional mutations in other
genes cannot be excluded.
In addition, caspase-1 activity can trigger TLR2-
and TLR4-mediated NF-kB activation.105 TLR2 and
TLR4 require MyD88 and MyD88 adaptor-like
(MAL) for signal transduction. Interestingly, caspase-
1 can physically interact with and cleave MAL, which is
required for subsequent activation of NF-kB and
MAPK. This has been demonstrated by inhibition of
caspase-1 activity or by overexpression of a MAL vari-
ant lacking the caspase-1 cleavage site, which blocks
TLR2- and TLR4-dependent NF-kB activation.105
Conclusions and perspectives
Inflammation is an essential pathway in host defense.
During the last 10 years different inflammasome com-
plexes have been identified, which all activate the pro-
tease caspase-1 and thereby the pro-inflammatory
cytokines proIL-1b and proIL-18. In addition, many
different DAMPs and PAMPs have been described
that activate inflammasomes. Inflammasomes are not
only involved in acute danger- or pathogen-associated
inflammation but also in the development of inflamma-
tion-driven diseases such as cancer, atherosclerosis and
type 2 diabetes mellitus.19 In addition, pyroptosis has
been identified as a novel form of programmed cell
death, which is caspase-1-dependent and supports
IL-1- or IL-18-driven inflammation.18 This is in sharp
contrast to apoptosis that does not activate the immune
system. Important unsolved questions are how inflam-
masomes and, particularly, the NLRP3 inflammasome
are activated at the molecular level. In addition, as not
a single substrate of caspase-1 in pyroptosis has been
identified, why is the enzyme’s activity needed for this
form of cell death? What is the relationship between
caspase-1 activation, activity and specificity? Recently,
a NLRP7 inflammasome has been identified, which
activates caspase-1 upon sensing of microbial lipopep-
tides.106 How many more types do exist and how is the
assembly of these inflammasome complexes triggered?
Is there a crosstalk between different inflammasome
complexes? How are caspase-1 activation and activity
regulated by post-translational modifications, such as
(de)ubiquitination and glutathionylation?107–109
Whereas most reports deal with IL-1b-, IL-18- and pyr-
optosis-mediated effects of caspase-1, the protease is
able to trigger additional pathways. Caspase-1 is cap-
able of supporting the survival of cells through trigger-
ing lipid metabolic pathways and most likely repair of
the damaged plasma membrane.93 In addition, activity
of the protease is required for unconventional secretion
of proteins involved in inflammation, repair, cytopro-
tection and apoptosis, and it is tempting to speculate
that also this pathway supports survival.96 However,
the substrates, which mediate these effects, are not
known and it will be a future task to identify them.
Caspase-1 inactivates enzymes involved in glycolysis
and activates the executioner caspase-7. However, the
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physiological relevance of these events remains to be
demonstrated.31,33 Caspase-1 has also been reported
to activate the transcription factor NF-kB independ-
ently of its enzymatic activity,100,101 which may result
in inflammation in vivo.104 Clearly, more efforts are
required to understand these effects – particularly the
generation of novel knock-in mouse models expressing
enzymatic inactive caspase-1. A major problem is the
fact that a lot of our knowledge about caspase-1 relies
on experiments with mice, which lack not only expres-
sion of caspase-1 but also of caspase-11.88 As mice defi-
cient only for caspase-1 are now available, the real
contribution of caspase-1 to inflammation can be
addressed. It has, however, to be taken into account
that in these mice caspase-11 has been reintroduced.
More advanced mouse genetics are also needed to
address the contribution of caspase-1 in single cell
types in vivo in more sophisticated inflammation
models and to discriminate between, for example, IL-
1-, IL-18- or pyroptosis-mediated effects. Owing to
obvious differences between mice and men, particularly
at the immunologic level, knock down studies with
human (primary) cells are very important for the ana-
lysis of the function of caspase-1 in humans. These
efforts should result in novel and specific therapies for
the numerous and different diseases caspase-1 is
involved in.
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